Powered by Max Banner Ads  

Computational Models of HIV-1 Resistance to Gene Therapy Elucidate Therapy Design Principles. PLoS Comput Biol. 2010;6(8): Authors: Aviran S, Shah PS, Schaffer DV, Arkin AP Gene therapy is an emerging alternative to conventional anti-HIV-1 drugs, and can potentially control the virus while alleviating major limitations of current approaches. Yet, HIV-1’s ability to rapidly acquire mutations and escape therapy presents a critical challenge to any novel treatment paradigm. Viral escape is thus a key consideration in the design of any gene-based technique. We develop a computational model of HIV’s evolutionary dynamics in vivo in the presence of a genetic therapy to explore the impact of therapy parameters and strategies on the development of resistance. Our model is generic and captures the properties of a broad class of gene-based agents that inhibit early stages of the viral life cycle. We highlight the differences in viral resistance dynamics between gene and standard antiretroviral therapies, and identify key factors that impact long-term viral suppression. In particular, we underscore the importance of mutationally-induced viral fitness losses in cells that are not genetically modified, as these can severely constrain the replication of resistant virus. We also propose and investigate a novel treatment strategy that leverages upon gene therapy’s unique capacity to deliver different genes to distinct cell populations, and we find that such a strategy can dramatically improve efficacy when used judiciously within a certain parametric regime. Finally, we revisit a previously-suggested idea of improving clinical outcomes by boosting the proliferation of the genetically-modified cells, but we find that such an approach has mixed effects on resistance dynamics. Our results provide insights into the short- and long-term effects of gene therapy and the role of its key properties in the evolution of resistance, which can serve as guidelines for the choice and optimization of effective therapeutic agents. PMID: 20711350 [PubMed - in process]

Original post:
Computational Models of HIV-1 Resistance to Gene Therapy Elucidate Therapy…

 | Posted by admin | Categories: Health, Medicine, Pharmaceuticals | Tagged: , , |

Related Articles N-alkylated oligoamide alpha-helical proteomimetics. Org Biomol Chem. 2010 May 21;8(10):2344-51 Authors: Campbell F, Plante JP, Edwards TA, Warriner SL, Wilson AJ Generic approaches for the design and synthesis of small molecule inhibitors of protein-protein interactions (PPIs) represent a key objective in modern chemical biology. Within this context, the alpha-helix mediated PPIs have received considerable attention as targets for inhibition using small molecules, foldamers and proteomimetics. This manuscript describes a novel N-alkylated aromatic oligoamide proteomimetic scaffold and its solid-phase synthesis–the first time such an approach has been used for proteomimetics. The utility of these scaffolds as proteomimetics is exemplified through the identification of potent microM inhibitors of the p53-hDM2 helix mediated PPI–a key oncogenic target. PMID: 20448891 [PubMed - indexed for MEDLINE]

See the original post:
N-alkylated oligoamide alpha-helical proteomimetics.

Click Here!



 Powered by Max Banner Ads